Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma

Thrift, Aaron P.; Pandeya, Nirmala; Whiteman, David C.

doi:10.3389/fonc.2012.00011

Cited by 29 publications

(24 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…74,75 In a Swedish nationwide case-control study, GERD and obesity were identified as strong and independent risk factors for EAC. 76 Barrett's esophagus Long standing GERD is strongly associated with development of Barrett's esophagus; the transformation of esophageal mucosal lining from normal stratified squamous to "intestine like" columnar epithelium with goblet cells (intestinal metaplasia).…”

Section: Reflux Disease Barrett's Esophagus (Be) and Esophageal Adenmentioning

confidence: 99%

Targeting chemokine pathways in esophageal adenocarcinoma

et al. 2014

View full text Add to dashboard Cite

y These authors Contributed equally to this work. E sophageal adenocarcinoma (EAC) is one of the fastest growing malignancies in the US and needs newer therapeutic and diagnostic strategies. Chronic inflammation plays a role in the pathogenesis of EAC and contributes to the dysplastic conversion of normal esophageal epithelium to Barrett's esophagus and frank adenocarcinoma. Chemokines play important roles in mediating inflammation and recent evidence implicates these ligands and their receptors in the development and spread of various tumors. We demonstrated that the chemokines IL8, CXCL1 and CXCL3 are significantly overexpressed during esophageal carcinogenesis and accompanied by amplification and demethylation of the chr4q21 gene locus. We also demonstrated that IL8 levels can be detected in serum of patients with EAC and can serve as potential biomarkers. We now demonstrate that inhibition of IL8 receptor, CXCR2, leads to decreased invasiveness of esophageal adenocarcinoma derived cells without affecting cellular proliferation. Taken together, these studies reveal the important roles that chemokines play in development of esophageal cancer and demonstrate that these pathways can serve as potential therapeutic targets.

show abstract

Section: Reflux Disease Barrett's Esophagus (Be) and Esophageal Adenmentioning

confidence: 99%

Targeting chemokine pathways in esophageal adenocarcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…According to our results and the previous reports, short-term infusional 5-FU and cisplatin combination in previously untreated locally advanced or metastatic esophageal squamous cell cancer were seem to be similar with continuous infusional 5-FU in terms of median OS and PFS. However, grade 3-4 toxicity rates were more frequent than infusional 5-FU except for grade [3][4] Despite the consideration of infusional chemotherapy as standard regimen for the treatment of esopahegeal cancer, there is a main problem with these regimens. This is the neccesity for a central venous catheter and ambulatory infusion pump.…”

Section: Discussionmentioning

confidence: 99%

“…Cancer of the esophagus typically occurs in one of two forms; upper two-thirds is a squamous cell carcinoma (SCC) and lower one-third is an adenocarcinoma.It is assumed that there are complete differences between esophageal adenocarcinomas and squamous cell cancer, such as the treatment protocol and prognosis. (1,2,3) Cytotoxic chemotherapy is the most effective treatment modality for esophageal cancer patients with metastatic disease. (4) Grunberger et al have showed that palliative chemotherapy can prolong the survival of metastatic esophageal cancer patients, relieve their symptoms and improve their quality of life.…”

Section: Introductionmentioning

confidence: 99%

First-line cisplatin plus bolus 5- Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer(Izmir Oncology Group Study)

Akyol¹,

Küçükzeybek²,

Varol³

et al. 2015

Acta Oncol Tur.

View full text Add to dashboard Cite

ÖZETAmaç: Sitotoksik kemoterapi, lokal ileri ve metastatik özefagus kanserinin standart tedavisidir. Biz bu çalı mada lokal ileri ve metastatik özefagus skuamoz hücreli kanserde birinci basamakta sisplatin ve kısa süreli infüzyonel 5-florourasil (5-FU) kombinasyonunun yararlarını ve yan etkilerini değerlendirdik.. Yöntem: Bu çalı mada, retrospektif olarak aralık 2006 ve temmuz 2013 tarihleri arasında sisplatin ve kısa süreli infüzyonel 5-florourasil (5-FU) kombinasyonu ile tedavi edilen daha önceden tedavi almamı lokal ileri veya metastatik özefagus skuamoz hücreli kanserli hastaları değerlendirdik. Kemoterapi rejimi olarak sisplatin 75 mg/m2 d1 (1-3-saat infuzyon), kalsiyum lökoverin 60 mg/m2 d1-2 ve 5-FU 500 mg/m2 d1-2 (15-dakika infuzyon) 14 günde bir uygulandı. Bulgular: Hastaların 14'ü (%51.9) erkek ve 13'ü (%48.1) kadın olup ortanca ya 57 (39-80) idi. ECOG performans skoru 20 (%77) hastada 0 veya 1 iken diğer hastalarda 2 olarak bulundu. Tanı anında 10 hasta uzak metastaza sahipken 17 hasta lokal ileri hastalığa sahipti. Hastalar medyan 4 kür kemoterapi aldı. Tüm yanıt oranı %44.4'tü. (8 hastada parsiyel yanıt,4 hasta komplet yanıt) ve 7 (%25.9) hasta stabil hastalığa sahipti. Hastalık kontrol oranı %70.3'tü. Hastaların medyan progresyonsuz sağkalımı 6.2 (%95 CI: 5.13 7.28) ve medyan genel sağkalımı 11.1 (%95 CI: 7.77-14.5) aydı. Hastaların % 40.7'sinde grade 3-4 nötropeni ve % 11.1'inde grade 3-4 trombositopeni saptandı. Sonuç: Sisplatin ve kısa süreli infüzyonel 5-florourasil (5-FU) kombinasyonu ilaç infuzyonu için kateter gerektiren infüzyonel rejime alternative bir tedavi olarak dü ünülebilir.Anahtar Kelimeler: Özefagus kanseri, lokal ileri, metastatic, sisplatin, 5-florourasil ABSTRACT Objectıve: Cytotoxic chemotherapy is the basic treatment for locally advanced and metastatic esophageal cancer. We evaluated the benefits and side effects of the first-line short-term infusional 5-Fluorouracil (5-FU) and cisplatin combination regimen in patients with locally advanced and metastatic esophageal squamous cell cancer. Methods: We retrospectively reviwed the untreated locally advanced or metastatic squamous cell esophageal cancer patients treated with short-term infusional 5-FU and cisplatin combination between December 2006 and july 2013. Chemotherapy regimen was administered as; cisplatin 75 mg/m2 on day 1 (1-3-h infusion), caleucovorin 60 mg/m2 d1-2 and 5-FU 500 mg/m2 d1-2 (15-min infusion) every 14 days. Results: There were 14 (51.9%) male and 13 (48.1%) female patients. The median age was 57 (range, 39-80) years. Twenty patients had an Eastern Cooperative Oncology Group performance status of 0 to 1 (77%), while the rest had PS of 2 (23%). At first diagnosis, 10 patients had distant metastases and 17 patients had localized disease. In total, 27 patients were treated with a median of four cycles. The overall response rate was 44.4% (8 partial responses, 4 complete responses) and 7 patients (25.9%) had stable disease. The disease control rate was 70.3%. Median progression free survival was 6.2 (95% CI: 5.1...

show abstract

“…19 Both acid and bile have been implicated as injurious and potentially mutagenic through direct DNA damage and activation of inflammatory pathways such as NF-kappa beta, which have downstream effects on cell proliferation. 20 Although reflux is very common, only a small proportion of people will go on to develop metaplasia, and it is likely that host genetic influences are important in this.…”

Section: Molecular Pathways Of Progression In Bomentioning

confidence: 99%

p53 Immunohistochemistry as a biomarker of dysplasia and neoplastic progression in Barrett's oesophagus

Kaye

2015

Diagnostic Histopathology

View full text Add to dashboard Cite

Current Status and Future Perspectives on the Etiology of Esophageal Adenocarcinoma

Cited by 29 publications

References 114 publications

Targeting chemokine pathways in esophageal adenocarcinoma

Targeting chemokine pathways in esophageal adenocarcinoma

First-line cisplatin plus bolus 5- Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer(Izmir Oncology Group Study)

p53 Immunohistochemistry as a biomarker of dysplasia and neoplastic progression in Barrett's oesophagus

Contact Info

Product

Resources

About